The status quo of targeted drug therapy in bladder cancer

Bladder cancer is one of the most common diseases in urology. The platinum-based chemotherapy is the standard treatment for locally advanced or metastatic bladder cancer, but it still has some obvious limits such as low efficacy, severe adverse effects and intolerance for some patients. Recently, targeted therapy is becoming a new approach for bladder cancer, which attracts more and more attention. This review summarizes current status and research progress of the application of five main kinds of targeted-therapy drugs for bladder cancer, including anti-angiogenesis agents, fibroblast growth factor family inhibitors, epidermal growth factor family inhibitors, MET signal pathway inhibitors and immune checkpoint inhibitors.